China yesterday defended its decision to overturn Pfizer's patent for Viagra in a ruling seen as a setback to protection of intellectual property rights in the country.
The US makers of the top selling erectile disfunction drug were in breach of China's intellectual property rights (IPR) law when they failed to accurately explain "technological" uses of Viagra's key ingredient, an official with the State Intellectual Property Office (SIPO) said.
"If you widen the description of the [ingredient's] technological uses, you could likely be violating the patent right of others," the SIPO official said on condition of anonymity.
PHOTO: AFP
Although the same office granted Pfizer in 2001 a patent for sildenafil citrate, Viagra's key active ingredient, the official maintained SIPO had the right to revoke the patent.
A Pfizer company statement promised to appeal the judgement.
The official said after approval of sildenafil citrate, more than 10 Chinese companies filed official complaints, forcing the SIPO to review its decision.
"When there are [domestic] requests to invalidate the patent, our review committee should go back to look to it," she said.
"We did grant the patent to Pfizer before, but that does not mean that we are really giving it to you," she said.
She further argued that given the potential size of the Chinese market the office could not afford to be imprudent.
"We are very cautious when we grant a patent, because a patent means a market, and that can mean allowing the monopolization of a market," she said.
The ruling has heightened concerns in the US and is likely to do so in the EU, as they have watched the case closely, concerned about intellectual property rights.
The US-China Business Council, a major Washington-based business association and lobby group, censured the decision and said it was "deeply concerned."
"Given how China has to strengthen IPR enforcement under its WTO obligations, its disheartening to see a lower-level agency make a decision clearly responding to pressure from Chinese companies," said the council's director, Patrick Powers.
Powers added the New York-based Pfizer, the world's largest pharmaceutical company, would take legal action in China, where foreign companies find their products are routinely copied and counterfeits are widespread.
China's decision likely does not augur well for the pharmaceutical industry, which has viewed the case as a litmus test for the protection of intellectual property rights.
"If China is going to embark on a strategy of patent nullification in order to avoid paying research and development costs, that does not bode well for a strong commitment to strengthening IPR," Powers said.
Pfizer plans to introduce up to 15 new medicines in China in the next five years to treat conditions such as neurological and cardiovascular problems, reports said.
"Intellectual property protection is essential to these plans," the company said.
Pfizer added that it "was extremely disheartened" by the move in China, where it had invested US$500 million by bringing advanced medicines, building facilities and hiring and training local employees.
A Viagra pill costs about one yuan (US$0.10) to make but Pfizer sells them in China for 98 yuan a tablet.
The entry of local producers is likely to see the price drop to 22 yuan a pill, the price of lookalike domestic products which do not contain Viagra's key ingredient.
DAREDEVIL: Honnold said it had always been a dream of his to climb Taipei 101, while a Netflix producer said the skyscraper was ‘a real icon of this country’ US climber Alex Honnold yesterday took on Taiwan’s tallest building, becoming the first person to scale Taipei 101 without a rope, harness or safety net. Hundreds of spectators gathered at the base of the 101-story skyscraper to watch Honnold, 40, embark on his daredevil feat, which was also broadcast live on Netflix. Dressed in a red T-shirt and yellow custom-made climbing shoes, Honnold swiftly moved up the southeast face of the glass and steel building. At one point, he stepped onto a platform midway up to wave down at fans and onlookers who were taking photos. People watching from inside
A Vietnamese migrant worker yesterday won NT$12 million (US$379,627) on a Lunar New Year scratch card in Kaohsiung as part of Taiwan Lottery Co’s (台灣彩券) “NT$12 Million Grand Fortune” (1200萬大吉利) game. The man was the first top-prize winner of the new game launched on Jan. 6 to mark the Lunar New Year. Three Vietnamese migrant workers visited a Taiwan Lottery shop on Xinyue Street in Kaohsiung’s Gangshan District (崗山), a store representative said. The player bought multiple tickets and, after winning nothing, held the final lottery ticket in one hand and rubbed the store’s statue of the Maitreya Buddha’s belly with the other,
‘NATO-PLUS’: ‘Our strategic partners in the Indo-Pacific are facing increasing aggression by the Chinese Communist Party,’ US Representative Rob Wittman said The US House of Representatives on Monday released its version of the Consolidated Appropriations Act, which includes US$1.15 billion to support security cooperation with Taiwan. The omnibus act, covering US$1.2 trillion of spending, allocates US$1 billion for the Taiwan Security Cooperation Initiative, as well as US$150 million for the replacement of defense articles and reimbursement of defense services provided to Taiwan. The fund allocations were based on the US National Defense Authorization Act for fiscal 2026 that was passed by the US Congress last month and authorized up to US$1 billion to the US Defense Security Cooperation Agency in support of the
HIGH-TECH DEAL: Chipmakers that expand in the US would be able to import up to 2.5 times their new capacity with no extra tariffs during an approved construction period Taiwan aims to build a “democratic” high-tech supply chain with the US and form a strategic artificial intelligence (AI) partnership under the new tariffs deal it sealed with Washington last week, Taipei’s top negotiator in the talks said yesterday. US President Donald Trump has pushed Taiwan, a major producer of semiconductors which runs a large trade surplus with the US, to invest more in the US, specifically in chips that power AI. Under the terms of the long-negotiated deal, chipmakers such as Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) that expand US production would incur a lower tariff on semiconductors or related manufacturing
RSS